Can a targeted drug boost standard ovarian cancer therapy?

NCT ID NCT07736937

Recruiting now Disease control Sponsor: Tubulis GmbH Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but still responds to platinum-based treatments. Researchers are looking for the best dose and watching for side effects, while also checking for early signs that the drug might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental antibody-drug conjugate called TUB-040 given with carboplatin and bevacizumab
What this could lead to: If successful, this could point toward a more effective treatment option for women with platinum-sensitive ovarian cancer.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove safe or effective. Side effects from the combination therapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube serous adenocarcinoma ovarian cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

ARENSIA Exploratory Medicine
NOT_YET_RECRUITING

Kyiv, Ukraine
CHU de Liege
RECRUITING

Liège, Belgium
Start Cal
NOT_YET_RECRUITING

Los Angeles, California, 90025, United States
Start Njeb
NOT_YET_RECRUITING

East Brunswick, New Jersey, 08816, United States
Start Nyli
NOT_YET_RECRUITING

New York, New York, 11042, United States
UCL Louvain
RECRUITING

Brussels, Belgium
UZ Gent
RECRUITING

Ghent, Belgium
UZ Leuven
RECRUITING

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.